The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Age: 12 - 17 years
Gender: All
We've found 1 total result for "Cardiomyopathy Hypertrophic".